Anti-Human MS4A1 Recombinant Antibody (1.5.3) (CAT#: TAB-1647CL)

Figure 1 The results of CellTiterGlo cell viability assays without cross-linking of Ramos cells incubated with mAbs 1.1.2, 1.2.1, 1.3.3, 1.4.3, 1.5.3, 1.6.2 and the Rituxan® (“Rituximab”) antibody control.

Percent viability of Ramos cells is shown on the y-axis and antibody concentration is shown on the x-axis.

Figure 2 The results of Alamar Blue cell viability assays without crosslinker of Ramos cells incubated with mAbs 1.6.2, 1.5.3, 1.4.3, (FIG. A) 1.3.3, 1.1.2, B1 (FIG. B) Rituximab, IgM and IgG1.

% viability is shown on the y-axis and antibody concentration is shown on the x-axis.

Figure 3 A scatterplot showing the results of a whole blood assay comparison of lytic activity using mAbs 1.5.3, 1.1.2, and Rituximab in a panel of cell lines.

Each symbol represents a human donor of whole blood. Percent lysis at 10 μg/ml is shown on the y-axis and the ARH-77, Daudi, EHEB, JMV2, MV3, Karpas422, Namalwa, Raji, Ramos, SC1, SU-DHL-4, and WSU-NHL cell lines, respectively, are shown on the x-axis.

Figure 4 A bar graph showing lysis of Rituximab-resistant cells RR1-Raji in a whole blood assay by Rituximab, mAb 1.1.2, and mAb 1.5.3.

The percentage lysis is shown on the y-axis and and Raji parental cells treated at a concentration of antibody of 1 μg/ml and 10 μg/ml, respectively and RR1-Raji cells treated at a concentration of antibody of 1 μg/ml and 10 μg/ml, respectively, are shown on the x-axis.

Figure 5 A line graph showing the effect of anti-CD20 antibodies, Rituximab, 2.1.2, 1.1.2, and 1.5.3 on mouse survival in a Ramos i.v. paralysis model (CB17 SCID).

The results show that three anti-CD20 antibodies demonstrate potent anti-lymphoma activity when administered as a single dose monotherapy. The number of days of treatment post tumor cell implantation is shown on the x-axis and percent survival is shown on the y-axis.

Figure 1 shows the results of cell viability assays without cross-linking of Ramos cells incubated with the antibody, and the Rituxan® ("Rituximab") antibody control.

Percent viability of Ramos cells is shown on the y-axis and antibody concentration is shown on the x-axis.

Figure 2 shows the results of Annexin V/PI apoptosis assays without cross-linker of Ramos cells incubated with mAbs.

Rituximab and Bl. % viability is shown on the y-axis and antibody concentration is on the x-axis.

Figure 3 shows the results of CDC assays of Ramos cell lines, respectively, incubated with mAbs.

Figure 4 is a graph shows results of an ADCC assay of Ramos cell line incubated with mAbs 2.1.2, 1.1-2, 1.5.3, 1.10.3.1, and 1.11.3.1, Rituximab, and IgGl control. % viability is showsn on the y-axis and antibody concentration is showsn on the x-axis.

Figure 5 is a line graph shows the effect of anti-CD20 antibodies, Rituximab, 2.1.2, 1.1.2, and 1.5.3 on mouse survival in a Ramos i.v. paralysis model (CB 17 SCID).

The results show that three anti-CD20 antibodies demonstrate potent anti- lymphoma activity when administered as a single dose monotherapy. The number of days of treatment post tumor cell implantation is shown on the x-axis and percent survival is shown on the y-axis.

Figure 6 is a line graph shows the efficacy of anti-CD20 antibodies in the Daudi subcutaneous tumor model.

The number of days of treatment after the time of tumor cell inoculation is shown on the x-axis and tumor volume in cubic millimeters is shown on the y-axis.